Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: A structural equation modeling approach

Psychoneuroendocrinology

Volumn 50, Issue , 2014, Pages 95-105

  Boyer, Laurent ^a   Testart, Julien ^b   Michel, Pierre ^a   Richieri, Raphaëlle ^b   Faget Agius, Catherine ^b   Vanoye, Violette ^b   Auquier, Pascal ^a   Lancon, Christophe ^a,b   Guedj, Eric ^c,d,e  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c TIMONE HOSPITAL   (France)

^d Aix Marseille University   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cerebral blood flow; Cognition; Metabolic syndrome; Schizophrenia; Single photon emission computed tomography (SPECT); SPM; Structural equation modeling

Indexed keywords

ADULT; ARTICLE; ATTENTION; BRAIN BLOOD FLOW; BRAIN PERFUSION; COGNITIVE DEFECT; CONNECTOME; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; INSULA; MAJOR CLINICAL STUDY; MALE; MEMORY; METABOLIC SYNDROME X; MIDDLE FRONTAL GYRUS; PREFRONTAL CORTEX; SCANNING ELECTRON MICROSCOPY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURAL EQUATION MODELING; SUPERIOR FRONTAL GYRUS; TASK PERFORMANCE; VOXEL BASED MORPHOMETRY; BRAIN; BRAIN CIRCULATION; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING; THEORETICAL MODEL;

ADULT; BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, THEORETICAL; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA;

EID: 84908433163     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.07.019     Document Type: Article

References (59)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 1993, 39-44.
2. APA DSM-IV. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC. 4th ed., text rev.
3. Baddeley A.D. Working Memory 1986, Oxford University Press, Oxford.
4. Baumstarck K., Boyer L., Boucekine M., Aghababian V., Parola N., Lancon C., Auquier P. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr. Res. 2013, 147(1):58-67.
5. Boyer L., Cermolacce M., Dassa D., Fernandez J., Boucekine M., Richieri R., Vaillant F., Dumas R., Auquier P., Lancon C. Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach. PLoS ONE 2012, 7:e47655.
6. Boyer L., Guedj E., Dassa D., Lancon C. Leber's hereditary optic neuropathy associated with schizophrenia. J. Clin. Psychiatry 2012, 73:e1158-e1159.
7. Boyer L., Richieri R., Dassa D., Boucekine M., Fernandez J., Vaillant F., Padovani R., Auquier P., Lancon C. Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Res. 2013, 10.1016/j.psychres.2013.06.020.
8. Boyer L., Richieri R., Faget C., Padovani R., Vaillant F., Mundler O., Lancon C., Auquier P., Guedj E. Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia. Psychiatry Res. 2012, 202:155-160.
9. Bray G.A. Obesity is a chronic, relapsing neurochemical disease. Int. J. Obes. Relat. Metab. Disord. 2004, 28:34-38.
10. Cheng A., Braunstein J.B., Dennison C., Nass C., Blumenthal R.S. Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. Clin. Cardiol. 2002, 25:205-212.
11. Cilia R., Cho S.S., van Eimeren T., Marotta G., Siri C., Ko J.H., Pellecchia G., Pezzoli G., Antonini A., Strafella A.P. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov. Disord. 2011, 26:225-233.
12. Cohen J. Statistical Power Analysis for Behavioural Sciences 1982, Lawrence Erlbaum Associates, Hillsdale, NJ.
13. Cohen J.I., Yates K.F., Duong M., Convit A. Obesity, orbitofrontal structure and function are associated with food choice: a cross-sectional study. BMJ Open 2011, 1:e000175.
14. Del Parigi A., Gautier J.F., Chen K., Salbe A.D., Ravussin E., Reiman E., Tataranni P.A. Neuroimaging and obesity: mapping the brain responses to hunger and satiation in humans using positron emission tomography. Ann. N. Y. Acad. Sci. 2002, 967:389-397.
15. Dichter G.S., Bellion C., Casp M., Belger A. Impaired modulation of attention and emotion in schizophrenia. Schizophr. Bull. 2010, 36:595-606.
16. Dickinson D., Gold J.M., Dickerson F.B., Medoff D., Dixon L.B. Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 2008, 49:123-131.
17. Dickinson D., Iannone V.N., Wilk C.M., Gold J.M. General and specific cognitive deficits in schizophrenia. Biol. Psychiatry 2004, 55:826-833.
18. Dik M.G., Jonker C., Comijs H.C., Deeg D.J., Kok A., Yaffe K., Penninx B.W. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007, 30:2655-2660.
19. Faget-Agius C., Boyer L., Padovani R., Richieri R., Mundler O., Lancon C., Guedj E. Schizophrenia with preserved insight is associated with increased perfusion of the precuneus. J. Psychiatry Neurosci. 2012, 37:110125.
20. Falissard B. Modèles structuraux. Comprendre et utiliser les statistiques dans les sciences de la vie 2005, 203-215. Masson, Paris. B. Falissard (Ed.).
21. Friedman J.I., Wallenstein S., Moshier E., Parrella M., White L., Bowler S., Gottlieb S., Harvey P.D., McGinn T.G., Flanagan L., Davis K.L. The effects of hypertension and body mass index on cognition in schizophrenia. Am. J. Psychiatry 2010, 167:1232-1239.
22. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 2004, 72:21-28.
23. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
24. Hassenstab J.J., Sweat V., Bruehl H., Convit A. Metabolic syndrome is associated with learning and recall impairment in middle age. Dement. Geriatr. Cogn. Disord. 2010, 29:356-362.
25. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
26. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
27. Holden K.F., Lindquist K., Tylavsky F.A., Rosano C., Harris T.B., Yaffe K. Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol. Aging 2009, 30:1483-1489.
28. Jaccard J., Wan C. LISREL Approaches to Interaction Effects in Multiple Regression 1996, Sage Publications, Thousand Oaks.
29. Kassi E., Pervanidou P., Kaltsas G., Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011, 9:48.
30. Kay S.R., Opler L.A., Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br. J. Psychiatry 1986, 149:439-448.
31. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647.
32. Konishi S., Hayashi T., Uchida I., Kikyo H., Takahashi E., Miyashita Y. Hemispheric asymmetry in human lateral prefrontal cortex during cognitive set shifting. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7803-7808.
33. Lancon C., Dassa D., Fernandez J., Richieri R., Padovani R., Boyer L. Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study. Cardiovasc. Psychiatry Neurol. 2012, 204043.
34. Lee D.S., Kang H., Kim H., Park H., Oh J.S., Lee J.S., Lee M.C. Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1681-1691.
35. Li X.L., Aou S., Oomura Y., Hori N., Fukunaga K., Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002, 113:607-615.
36. Lindenmayer J.P., Khan A., Kaushik S., Thanju A., Praveen R., Hoffman L., Cherath L., Valdez G., Wance D. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr. Res. 2012, 142:171-176.
37. McGurk S.R., Mueser K.T., Walling D., Harvey P.D., Meltzer H.Y. Cognitive functioning predicts outpatient service utilization in schizophrenia. Ment. Health Serv. Res. 2004, 6:185-188.
38. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., Patel J.K., Keefe R.S., Stroup T.S., Lieberman J.A. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 2005, 80:9-18.
39. Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., van Berckel B.N., Ossenkoppele R., Guedj E., Didic M., Brugnolo A., Sambuceti G., Pagani M., Salmon E., Nobili F. Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol. Aging 2012, 33:2533-2550.
40. Nakamura M., Nestor P.G., Levitt J.J., Cohen A.S., Kawashima T., Shenton M.E., McCarley R.W. Orbitofrontal volume deficit in schizophrenia and thought disorder. Brain 2008, 131:180-195.
41. Nasrallah H.A. Linkage of cognitive impairments with metabolic disorders in schizophrenia. Am. J. Psychiatry 2010, 167:1155-1157.
42. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
43. Nuechterlein K.H., Subotnik K.L., Ventura J., Green M.F., Gretchen-Doorly D., Asarnow R.F. The puzzle of schizophrenia: tracking the core role of cognitive deficits. Dev. Psychopathol. 2012, 24:529-536.
44. Godefroy, O., GREFEX éditeur, 2008. Fonctions executives et pathologies neurologiques et psychiatriques Solal (Ed.), Evaluation en pratique clinique, Collection neuropsychologie, Marseille, France.
45. Oomura Y., Hori N., Shiraishi T., Fukunaga K., Takeda H., Tsuji M., Matsumiya T., Ishibashi M., Aou S., Li X.L., Kohno D., Uramura K., Sougawa H., Yada T., Wayner M.J., Sasaki K. Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 2006, 27:2738-2749.
46. Pauly K., Seiferth N.Y., Kellermann T., Ruhrmann S., Daumann B., Backes V., Klosterkotter J., Shah N.J., Schneider F., Kircher T.T., Habel U. The interaction of working memory and emotion in persons clinically at risk for psychosis: an fMRI pilot study. Schizophr. Res. 2010, 120:167-176.
47. Rodriguez-Sanchez J.M., Crespo-Facorro B., Perez-Iglesias R., Gonzalez-Blanch C., Alvarez-Jimenez M., Llorca J., Vazquez-Barquero J.L. Prefrontal cognitive functions in stabilized first-episode patients with schizophrenia spectrum disorders: a dissociation between dorsolateral and orbitofrontal functioning. Schizophr. Res. 2005, 77:279-288.
48. Rolls E.T. Understanding the mechanisms of food intake and obesity. Obes. Rev. 2007, 8(Suppl. 1):67-72.
49. Schoenbaum G., Roesch M.R., Stalnaker T.A. Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci. 2006, 29:116-124.
50. Szatkowska I., Szymanska O., Bojarski P., Grabowska A. Cognitive inhibition in patients with medial orbitofrontal damage. Exp. Brain Res. 2007, 181:109-115.
51. Szoke A., Trandafir A., Dupont M.E., Meary A., Schurhoff F., Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br. J. Psychiatry 2008, 192:248-257.
52. Tchanturia K., Lock J. Cognitive remediation therapy for eating disorders: development, refinement and future directions. Curr. Top. Behav. Neurosci. 2011, 6:269-287.
53. van den Berg E., Kloppenborg R.P., Kessels R.P., Kappelle L.J., Biessels G.J. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim. Biophys. Acta 2009, 1792:470-481.
54. Viviani R., Messina I., Walter M. Resting state functional connectivity in perfusion imaging: correlation maps with BOLD connectivity and resting state perfusion. PLoS ONE 2011, 6:e27050.
55. Willeumier K.C., Taylor D.V., Amen D.G. Elevated BMI is associated with decreased blood flow in the prefrontal cortex using SPECT imaging in healthy adults. Obesity (Silver Spring) 2011, 19:1095-1097.
56. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237-2242.
57. Yau P.L., Castro M.G., Tagani A., Tsui W.H., Convit A. Obesity and metabolic syndrome and functional and structural brain impairments in adolescence. Pediatrics 2012, 130:e856-e864.
58. Zakzanis K.K., Mraz R., Graham S.J. An fMRI study of the Trail Making Test. Neuropsychologia 2005, 43:1878-1886.
59. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.